Peter Attia· MD
for me minimizing hyperinsulinemia becomes very important and and I suspect we'll probably have an entire discussion on the role of IGF in cancer and IGF bp3 because I think it's actually quite controversial
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
for me minimizing hyperinsulinemia becomes very important and and I suspect we'll probably have an entire discussion on the role of IGF in cancer and IGF bp3 because I think it's actually quite controversial
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
So in cancer it really comes down to understanding inflammation, which we've already addressed, and metabolic health, which again was also part of the cardiovascular stuff, though I didn't go into it. But so for me, minimizing hyperinsulinemia becomes very important. And I suspect we'll probably have an entire discussion on the role of IGF in cancer and IGF-BP3, because I think it's actually quite controversial.
and we have these new epidemiology papers coming out showing both that insulin as coral you know elevated insulin hyperinsulinemia is correlated with cancer